Boryung Pharmaceutical’s antihypertensive treatment Kanarb marked the largest production among 29 locally developed new drugs in 2017, government data showed Thursday.
According to data from the Ministry of Food and Drug Safety, productions of novel drugs by domestic pharmaceuticals amounted to 184.8 billion won ($164.7 million) last year, up 10.1 percent from 167.8 billion won in 2016.
|Boryung Pharma’s Kanarb family medicines Dukarb (from left), Tuvero, and Kanarb|
Kanarb’s output reached 40.2 billion won, followed by LG Chem’s Zemiglo, an antidiabetic drug, with 32.7 billion won. Il-yang Pharmaceutical’s antiulcer treatment Noltec marked 26.1 billion won production.
Dongwha Pharm’s Zabolante, a treatment for the chronic obstructive pulmonary disease, achieved the most significant output growth. Its annual production spiked 652 percent from a year earlier.
The output of Il-yang’s anticancer medicine Supect jumped 229 percent year-on-year during the cited period, and that of Daewon Pharm’s arthritis treatment Pelubi, 88.4 percent.
Celltrion ranked first in output among drug suppliers, producing 902.3 billion won worth medicines last year. The company’s production rose 110.6 percent year-on-year. Hanmi Pharmaceutical came next with 759.6 billion won, followed by Chong Kun Dang’s 717.8 billion won, and Daewoong Pharmaceutical’s 668.2 billion won.
Among all finished drugs, Handok’s arteriosclerosis treatment Plavix topped the production with 84.5 billion won, stepping up from the No. 2 position last year. GC’s Human Serum Albumin Inj. ranked second with 81 billion won, followed by Samjin Pharm’s Platless with 78.7 billion won.
Among raw drug materials, Celltrion’s Remsima concentrate for solution marked 367.1 billion won output and continued to occupy the No.1 spot from last year. The company’s Truxima concentrate for solution ranked second with 347.3 billion won production, and Herzuma concentrates for solution, third with 96.8 billion won.
<© Korea Biomedical Review, All rights reserved.>